Amneal Pharmaceuticals, Inc.
Market Cap
$3.91B
P/E Ratio
56.50
EPS
$0.22
Dividend Yield
0.00%
52-Week Range
$6.68 — $15.42
Volume
2.49M
Avg Volume
2.59M
Beta
1.30
P/E (TTM)
56.50
Forward P/E
12.89
PEG Ratio
0.05
P/S (TTM)
1.38
P/B (TTM)
-58.65
P/FCF
30.41
EV/EBITDA
50.41x
EV/Sales
—
ROE (TTM)
-0.68%
ROA (TTM)
0.02%
ROIC
-0.00%
Gross Margin
0.37%
Operating Margin
0.11%
Net Margin
0.00%
Debt/Equity
-38.65
Current Ratio
2.17
EPS Growth (YoY)
+15.97%
Revenue Growth (YoY)
+0.10%
EPS Growth (3Y)
-4.21%
EPS Growth (5Y)
-2.48%
Sales Growth (3Y)
+0.10%
Sales Growth (5Y)
+0.12%
EPS Est (This Year)
$0.96
EPS Est (Next Year)
$1.17
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.99
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $16.00(28.7% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
0
Outstanding Shares
314.63M
Float
156.91M
Free Float %
49.87%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
NASDAQ
IPO Date
2018-05-07
Employees
8300
CEO
Chirag K. Patel
Index Membership
—
Website
https://www.amneal.com
Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $3.91B, a P/E ratio of 56.50, AMRX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare AMRX against other stocks using dozens of fundamental and technical filters.
Amneal Pharmaceuticals, Inc. (AMRX) has a trailing twelve-month (TTM) P/E ratio of 56.50. This is above the market average, which may reflect high growth expectations or premium valuation. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Amneal Pharmaceuticals, Inc. (AMRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $3.91 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Amneal Pharmaceuticals, Inc. (AMRX) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $16.00 implies 28.7% upside from the current price.